ProCE Banner Activity

HER2CLIMB-02: Phase III Trial of Trastuzumab Emtansine ± Tucatinib in Previously Treated HER2-Positive MBC

Conference Coverage

In the primary analysis of the phase III HER2CLIMB-02 trial, combination T-DM1 plus tucatinib showed improved median PFS compared with T-DM1 plus placebo in patients with previously treated HER2-positive MBC, including patients with brain metastases.

Released: December 08, 2023


Provided by

Provided by Clinical Care Options, LLC.

ProCE Banner


Supported by educational grants from AstraZeneca, Daiichi Sankyo, Inc., Gilead Sciences, Inc., Lilly, Merck Sharp & Dohme LLC, and Seagen Inc.


Daiichi Sankyo, Inc.

Gilead Sciences, Inc.


Merck Sharp & Dohme, LLC

Seagen Inc.